Watsco 2025 Q3 Earnings Revenue Drops 4.3%, EPS Falls 6.1%

Generated by AI AgentDaily EarningsReviewed byTianhao Xu
Saturday, Nov 8, 2025 5:16 pm ET1min read
Aime RobotAime Summary

-

(WSO) reported Q3 2025 earnings with 4.3% revenue decline and 6.1% EPS drop, missing expectations.

- UBS cut its price target to $390 as shares gained 1.00% daily but fell 11.30% month-to-date amid mixed momentum.

- Improved 27.5% gross margins and $355M cash flow highlighted resilience despite net income falling 6.2% year-over-year.

- Analysts maintained "Hold" rating, noting CEO's focus on margin expansion and e-commerce growth amid market volatility.

Watsco (WSO) reported fiscal 2025 Q3 earnings on Nov 8, 2025, with results falling below expectations. , , . UBS Group revised its price target for

to $390, . The stock has faced mixed momentum, gaining 1.00% daily but declining 11.30% month-to-date. Analysts remain divided, with a consensus "Hold" rating.

Revenue

, .

Earnings/Net Income

. Meanwhile, , down 6.2% from $201.65 million reported in 2024 Q3. The EPS and net income declines indicate a challenging quarter for

, with both metrics falling short of prior year levels.

Price Action

The stock price of Watsco has edged up 1.00% during the latest trading day, has dropped 4.45% during the most recent full trading week, .

Post-Earnings Price Action Review

Watsco’s improved gross margins (27.5%) and record third-quarter cash flow of $355 million underscore its financial resilience. , . . , a 10.40% premium, aligns with analysts’ cautious optimism. While the strategy of buying on revenue beats and holding for 30 days appears compelling, investors should remain mindful of market volatility.

CEO Commentary

The provided data lacks direct CEO commentary from the earnings call. Key insights from the report include the CEO’s emphasis on margin expansion, e-commerce growth, and financial flexibility.

Guidance

. , .

Additional News

, . , with SJS Investment Consulting Inc. . , , , . . , .

.

Comments



Add a public comment...
No comments

No comments yet